FOR IMMEDIATE RELEASE
Global EDC Provider Adds Two Executives to Head Growing Tokyo Office
and Support Increasing Demand in Asian Markets
CMO Dr. Ed Ikeguchi and CTO Glen de Vries to Present at DIA Japan’s
9th Annual Workshop for Clinical Data Management
NEW YORK, NY – January 18, 2006 – Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced the addition of two senior-level executives to serve the increasing demand for its Rave solution within the Japanese pharmaceutical market. Building on Medidata’s established presence in the U.S. and EMEA, the growing Japan office will continue to enable Asia–Pacific’s ability to implement clinical trial technologies that increase safety and efficiency, decrease costs and boost patient enrollment.
The Japanese pharmaceutical market is currently the second-largest in the world behind the U.S. and the largest market in Asia–Pacific, holding 67.3 percent of the market’s total value, according to Datamonitor. To lead its implementation services in the region, Medidata Solutions has appointed Hiroto Ohno as senior director of Japan operations. Ohno formerly served as assistant director of clinical data management, biostatistics and medical writing at Amgen Japan and brings more than 17 years of experience in drug development at global pharmaceutical companies and contract research organizations.
In addition to the current sales and implementation teams, Ohno will be joined by new Medidata Sales Executive Takeru Yamamoto, who previously held various managementlevel consulting positions and worked to introduce electronic data capture systems to the Japanese market.
“With increasing opportunity in Japan and other parts of Asia and the pace of regulatory reform, many Japanese pharmaceutical companies are continuing to enhance strategies to decrease operating costs and bring new drugs to market more efficiently,” said Glen de Vries, CTO of Medidata Solutions. “With its ability to consolidate data management and provide Web-enabled data entry across geographic locations and in multiple languages simultaneously, Medidata’s Rave platform is ideal for those looking to streamline both clinical trials within Japan and to scale internationally to compete in today’s global economy.”
Both Ohno and Yamamoto will be attending the upcoming Drug Information Association (DIA) 9th Annual Workshop in Japan for Clinical Data Management, to be held in Tokyo on January 26–27, 2006. In addition, Medidata’s Chief Medical Officer Dr. Ed Ikeguchi and Chief Technology Officer Glen de Vries will be presenting in two separate sessions at the event. Ikeguchi will be presenting on “Understanding the Return on Investments of EDC,” on Thursday, January 26th at 4:30 p.m. De Vries’ presentation, “Increasing Data Manager Productivity with Self-Documenting Systems,” is scheduled after Ikeguchi’s on Thursday, January 26th at 5:00 p.m.
“Japan continues to maintain a leading role in the global pharmaceutical market and has consistently remained at the forefront of clinical trial technology,” said Tarek Sherif, CEO of Medidata Solutions. “Medidata’s strategic decision to invest in a highly-skilled and talented management team to lead our growing Tokyo office demonstrates our commitment to expanding our services and strengthening our position in the Asian marketplace.”
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology and medical device companies realize the maximum potential value from their clinical research investments. Working with companies large and small, Medidata Solutions helps accelerate the process of bringing life-enhancing treatments to market—on five continents and in more than 70 countries. Innovative process design, technology and services can streamline clinical trials by providing early visibility to clinical data for faster decision-making, optimized resources and lower execution risk. Medidata Solutions’ broad client base and deep clinical experience provide value for the world’s leading pharmaceutical, biotechnology and medical device companies, expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. To learn more about Medidata Solutions, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com